Zobrazeno 1 - 10 of 88 pro vyhledávání: '"Paclitaxel/administration & dosage"'
1
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial
Autor: M. Gershenson, David, Miller, Austin, E Brady, William, Paul, James, Carty, Karen, Rodgers, William, Millan, David, L Coleman, Robert, N Moore, Kathleen, Banerjee, Susana, Connolly, Kate, Alvarez Secord, Angeles, M O'Malley, David, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robb, Herrington, C Simon, Q Huang, Helen, B Wenzel, Lari, Gourley, Charlie
Publikováno v: M. Gershenson, D, Miller, A, E Brady, W, Paul, J, Carty, K, Rodgers, W, Millan, D, L Coleman, R, N Moore, K, Banerjee, S, Connolly, K, Alvarez Secord, A, M O'Malley, D, Dorigo, O, Gaillard, S, Gabra, H, Slomovitz, B, Hanjani, P, Farley, J, Churchman, M, Ewing, A, Hollis, R, Herrington, C S, Q Huang, H, B Wenzel, L & Gourley, C 2022, ' Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial ', The Lancet, vol. 399, no. 10324, pp. 541-553 . https://doi.org/10.1016/S0140-6736(21)02175-9
BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician'
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3094::10daf3830e8817199b8469c4d2ece72c
https://hdl.handle.net/20.500.11820/745251c7-7e6d-4cf1-9129-3a76f1637764
Zobrazit plný text záznamu
2
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Autor: Aikou Okamoto, Ana Oaknin, Elizabeth M. Swisher, Shibani Nicum, Mika Mizuno, Robert L. Coleman, Karina Dahl Steffensen, Sudipta Bhattacharya, Gini F. Fleming, Paul DiSilvestro, Mark A. Morgan, Charles A. Leath, Peter Ansell, Christine K. Ratajczak, Andrea R. Hagemann, Carol Aghajanian, Kathleen N. Moore, Michael Friedlander, Joo-Hyun Nam, Danielle Sullivan, Noa Ben-Baruch, Katherine M. Bell-McGuinn, Minh H. Dinh, Bruce A. Bach, Michael A. Bookman, Theresa L. Werner, Mark F. Brady, Jesús García-Donas, N.G. Cloven, Sally Baron-Hay, Ramey D. Littell, David Cella
Publikováno v: Coleman, R L, Fleming, G F, Brady, M F, Swisher, E M, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K N, Efrat Ben-Baruch, N, Werner, T L, Cloven, N G, Oaknin, A, DiSilvestro, P A, Morgan, M A, Nam, J-H, Leath, C A, Nicum, S, Hagemann, A R, Littell, R D, Cella, D, Baron-Hay, S, Garcia-Donas, J, Mizuno, M, Bell-McGuinn, K, Sullivan, D M, Bach, B A, Bhattacharya, S, Ratajczak, C K, Ansell, P J, Dinh, M H, Aghajanian, C & Bookman, M A 2019, ' Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer ', The New England Journal of Medicine, vol. 381, no. 25, pp. 2403-2415 . https://doi.org/10.1056/NEJMoa1909707
BACKGROUND: Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca7b04b7c61e036ac9e46850f4d7173
https://doi.org/10.1056/nejmoa1909707
Zobrazit plný text záznamu
3
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3)
Publikováno v: Lancet oncology. 19(3):295-309
Background Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::ae26946dc823824d4fb303648e21ae91
https://doi.org/10.1016/s1470-2045(18)30079-2
Zobrazit plný text záznamu
4
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Autor: Boer, S.M. de, Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.H., Jurgenliemk-Schulz, I.M., Kitchener, H.C., Nijman, H.W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D., Hanzen, C., Lutgens, L.C.H.W., Smit, V.T.H.B.M., Singh, N., V. do, D'Amico, R., Nout, R.A., Feeney, A., Verhoeven-Adema, K.W., Putter, H., Creutzberg, C.L., PORTEC Study Grp
Publikováno v: Lancet Oncology, 19(3), 295-309. ELSEVIER SCIENCE INC
The Lancet Oncology, 19(3), 295-309
Lancet Oncology, 19, 3, pp. 295-309
Lancet oncology, 19(3), 295-309. Elsevier Science
Lancet Oncology, 19, 295-309
Background Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::11bd42e0bdc9d24ffed3f32e687ad960
https://doi.org/10.1016/s1470-2045(18)30079-2
Zobrazit plný text záznamu
5
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Autor: Ron H.J. Mathijssen, Jan H.M. Schellens, Aurelia H. M. de Vries Schultink, Markus Joerger, Marie-Rose B S Crombag, Thomas P. C. Dorlo, Sophie Wijngaard, Stijn L.W. Koolen, Alwin D. R. Huitema, Jos H. Beijnen, Nielka P. van Erp
Publikováno v: Pharmaceutical Research, 36(2):33. Springer New York
Pharmaceutical Research, 36, 2
Pharmaceutical Research, 36
Pharmaceutical Research, 36(2). Springer New York LLC
Pharmaceutical Research, 36(2). Springer New York
Purpose: Limited available data suggest that older patients are more prone to develop paclitaxel-induced toxicity than their younger peers. It remains unclear whether this is related to age-dependent pharmacokinetics (PK) of paclitaxel. Primary objec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e404eecabc63644ec7140112323f5d
https://pure.eur.nl/en/publications/6c0becb1-1fbd-4370-906d-beab6e7b1f76
Zobrazit plný text záznamu
7
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial
Autor: de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., Stam, Tanja C.
Publikováno v: The Lancet Oncology, 19(3), 295. Lancet Publishing Group
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::4feaf5e077dbd4f97c20b4cb4e899ff9
https://dspace.library.uu.nl/handle/1874/363891
Zobrazit plný text záznamu
8
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
Autor: Shannon Puhalla, M. Friedlander, Igor Bondarenko, Caroline Nickner, Qin Qin, Steven J. Isakoff, Paul K. Marcom, M. Campone, Erik Jakobsen, Judy Garber, E. Chmielowska, M Palácová, Christine K. Ratajczak, H.S. Han, William J. Gradishar, Melinda L. Telli, Mark E. Robson, Jane Qian, Agnes Jager, Susan M. Domchek, D Citrin, Virginia G. Kaklamani, Yaroslav Shparyk, Stacie Peacock Shepherd, Bella Kaufman, Véronique Diéras
Publikováno v: Annals of Oncology, 29(1), 154-161. Elsevier Ltd.
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6245faf8fe340df6bb665b1a1db5b1a
https://pure.eur.nl/en/publications/f335467b-a340-4640-9706-dda834d92443
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
ICORG 10-14:NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
Autor: J Mellor, Lars Bo Svendsen, M Illsley, Christophe Mariette, K Hofland, S. M. Griffin, G O’Dowd, Narayanasamy Ravi, George B. Hanna, R Mc Dermott, Claire L. Donohoe, Bryan T. Hennessy, Sinead Cuffe, Dermot O'Toole, Gregory D. Leonard, K Lee, K. Scott, G Jones, I Parker, Shaun R. Preston, Lene Baeksgaard, M Cunnane, Pablo M. Lawner, Tom Crosby, Seamus O'Reilly, V Marchesin, C Johnson, Cian Muldoon, AK Corkhill, S Warren, John V. Reynolds, Moya Cunningham, M Dib, B O’Neill
Publikováno v: Reynolds, J V, Preston, S R, O'Neill, B, Baeksgaard, L, Griffin, S M, Mariette, C, Cuffe, S, Cunningham, M, Crosby, T, Parker, I, Hofland, K, Hanna, G, Svendsen, L B, Donohoe, C L, Muldoon, C, O'Toole, D, Johnson, C, Ravi, N, Jones, G, Corkhill, A K, Illsley, M, Mellor, J, Lee, K, Dib, M, Marchesin, V, Cunnane, M, Scott, K, Lawner, P, Warren, S, O'Reilly, S, O'Dowd, G, Leonard, G, Hennessy, B & Dermott, R M 2017, ' ICORG 10-14 : NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) ', B M C Cancer, vol. 17, 401 . https://doi.org/10.1186/s12885-017-3386-2
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
Background Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemoth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b993161e8515b06273bfc9a1e222ce7
https://curis.ku.dk/portal/da/publications/icorg-1014(31db130e-532e-4195-a5bb-f2b3044ce10c).html
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje